Survodutide's twin — same mechanism, but this one is already approved. Three points make this entry land: (1) it's the same GLP-1 / glucagon dual class as Survodutide (#6), but built as an oxyntomodulin analog — and, crucially, it is the first GLP-1/glucagon dual agonist approved anywhere in the wor
Mazdutide is a GLP-1 / glucagon dual-agonist peptide — the same mechanism as Survodutide (#6) — but designed as an oxyntomodulin analog and co-developed by Innovent and Eli Lilly. Its defining fact: in June 2025 it became the first GLP-1/glucagon dual agonist approved anywhere in the world (China NMPA, for weight management; T2D followed in September). The glucagon arm gives it the class-typical extras — increased energy expenditure and hepatic fat oxidation, plus notable visceral-fat reduction — on top of GLP-1 appetite suppression. Efficacy is strong: GLORY-2 reached ~20.1% weight loss at over 60 weeks (the tirzepatide tier) with only a two-step dose titration, and in the DREAMS-3 head-to-head it beat semaglutide on both weight and HbA1c. Tolerability is the usual GLP-1 GI profile (nausea/diarrhea/vomiting, mostly mild-moderate and transient; ~2.9% discontinuation in GLORY-2). The honest caveat: the pivotal evidence is entirely in Chinese populations, and it is approved only in China — global trials/approvals are still pending.
not approved outside China; investigational elsewhere. Not a cosmetic; no compounding pathway.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (China-approved; watch for global (non-Chinese) trials and any ex-China regulatory filing, which would change the region-qualified grades).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.